LEČENJE COVID-19 PRIMENOM LEKA CASIRIVIMAB/INDEVIMAB KOD PACIJENTA SA POVREDOM VRATNOG DELA KIČME, PRIKAZ SLUČAJA

Miljana Vrhovac; Tijana Stanišić; Milan Mirković; Jelena  Veličković; Sead Dalifi; Danilo Jeremić; Filip Pilipović; Tatjana Adžić-Vukičević

doi:10.5937/smclk6-55371

Miljana Vrhovac Univerzitetski klinički centar Srbije, Kovid bolnica Batajnica, Beograd, Srbija
Tijana Stanišić Univerzitetski klinički centar Srbije, Kovid bolnica Batajnica, Beograd, Srbija; Univerzitetski klinički centar Srbije, Centar za fizikalnu medicinu i rehabilitaciju, Beograd, Srbija
Milan Mirković Institut za ortopediju „Banjica”, Beograd, Srbija
Jelena Veličković Univerzitetski klinički centar Srbije, Kovid bolnica Batajnica, Beograd, Srbija; Univerzitet u Beogradu, Medicinski fakultet, Beograd, Srbija; Univerzitetski klinički centar Srbije, Centar za anesteziju i reanimaciju, Beograd, Srbija
Sead Dalifi Univerzitetski klinički centar Srbije, Kovid bolnica Batajnica, Beograd, Srbija; Univerzitetski klinički centar Srbije, Klinika za pulmologiju, Beograd, Srbija
Danilo Jeremić Institut za ortopediju „Banjica”, Beograd, Srbija; Univerzitet u Beogradu, Medicinski fakultet, Beograd, Srbija
Filip Pilipović Institut za ortopediju „Banjica”, Beograd, Srbija
Tatjana Adžić-Vukičević Univerzitetski klinički centar Srbije, Kovid bolnica Batajnica, Beograd, Srbija; Univerzitetski klinički centar Srbije, Centar za anesteziju i reanimaciju, Beograd, Srbija; Univerzitetski klinički centar Srbije, Klinika za pulmologiju, Beograd, Srbija

DOI: https://doi.org/10.5937/smclk6-55371

Ključne reči: COVID-19, casirivimab/indevimab, terapija monoklonskim antitelima, povreda vratne kičme

Sažetak

Uvod/Cilj: Prikazujemo pacijenta obolelog od COVID-19 sa povredom vratne kičme koji je lečen primenom antivirusnog leka casirivimab/indevimab (Regen-CoV), monoklonskih antitela za COVID-19, u toku bolničkog lečenja u Kovid bolnici Batajnica Univerzitetskog kliničkog centra Srbije.

Prikaz slučaja: Primena leka casirivimab/indevimab (Regen-CoV) sprečila je razvoj teže slike Covida-19 i dovela je do brze negativizacije nazofaringealnog brisa na SARS-CoV-2 kod našeg pacijenta koji je imao povredu vratne kičme. Pacijentu je uspešno izvršena operacija vratne kičme u Institutu za ortopedsko-hirurške bolesti Banjica, koja je dovela do povlačenja neuroloških deficita koje je imao ranije.

Zaključak: Pokazali smo još jednu veoma važnu indikaciju za primenu leka casirivimab/indevimab (Regen-CoV) u bolničkim uslovima, koja je, po terapijskim Protokolima, bila off-label.

Reference

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. Trial Investigators. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021 Dec 2;385(23):e81. doi: 10.1056/NEJMoa2108163.

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021 Apr 21 – 2024 Mar 1 [cited 2022 Mar 16]. Available from: https://www.covid19treatmentguidelines.nih.gov/.

Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020 May 28;181(5):1036-45.e9. doi: 10.1016/j.cell.2020.04.026.

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-51. doi: 10.1056/NEJMoa2035002.

Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020 May 14;181(4):894-904.e9. doi: 10.1016/j.cell.2020.03.045.

Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020 Nov 27;370(6520):1110-5. doi: 10.1126/science.abe2402.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8. doi: 10.1126/science.abb2762.

Copin R, Baum A, Wloga E, Pascal KE, Giordano S, Fulton BO, et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. 2021 Jul 22;184(15):3949-61.e11. doi: 10.1016/j.cell.2021.06.002.

Ballotta L, Simonetti O, D’Agaro P, Segat L, Koncan R, Martinez-Orellana P, et al. Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: the emerging therapeutic role of casirivimab/imdevimab. Front Oncol. 2022 Sep 30;12:945060. doi: 10.3389/fonc.2022.945060.

Palomba E, Carrabba M, Zuglian G, Alagna L, Saltini P, Fortina V, et al. Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia, Int J Infect Dis. 2021 Sep;110:338-40. doi: 10.1016/j.ijid.2021.07.064.

Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020 Aug 21;369(6506):1014-8. doi: 10.1126/science.abd0831.

Gilbert DN, Chambers HF, Saag MS, Pavia AT, Boucher HW, Sanford JC. The Sanford guide to antimicrobial therapy. 52nd ed. Sperryville, VA, USA: Antimicrobial Therapy, Inc; 2022. 317 p.

Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyciński J, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat. 2021 Dec;59:100794. doi: 10.1016/j.drup.2021.100794.

O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, et al. Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021 Sep 23;385(13):1184-95. doi: 10.1056/NEJMoa2109682.

Centers for Medicare and Medicaid Services. CMS adult elective surgery and procedure recommendations: limit all non-essential planned surgeries and procedures, including dental, until further notice [Internet]. 2020 March 15 [accessed 2020 April 1]. Available from: https://www.cms.gov/files/document/31820-cms-adult-elective-surgery-and-procedures-recommendations.pdf

American College of Surgeons. ACS recommendations for management of elective surgical procedures [Internet]. 2020 March 13 [accessed 2020 April 1]. Available from: https://www.facs.org/media/b04pkoxp/recommendations_for_management_of_elective_surgical_procedures.pdf

Moletta L, Pierobon ES, Capovilla G, Costantini M, Salvador R, Merigliano S, et al. International guidelines and recommendations for surgery during Covid-19 pandemic: a systematic review. Int J Surg. 2020 Jul;79:180-8. doi: 10.1016/j.ijsu.2020.05.061.

American College of Surgeons, American Society of Anesthesiologists, Association of periOperative Registered Nurses, American Hospital Association. Joint statement: roadmap for resuming elective surgery after COVID-19 pandemic [Internet]. 2020 April 16 [accessed 2020 April 22]. Available from: https://www.asahq.org/about-asa/newsroom/news-releases/2020/04/joint-statement-on-elective-surgery-after-covid-19-pandemic/.

Jain NS, Alluri RK, Schopler SS, Hah R, Wang JC. COVID-19 and spine surgery: a review and evolving recommendations. Global Spine J. 2020 Aug;10(5):528-33. doi: 10.1177/2192568220923655.

Idrizi A, Gordon AM, Lam A, Conway C, Saleh A. The effect of the coronavirus disease 2019 (COVID-19) pandemic on elective cervical spine surgery utilization and complications in the United States: a nationwide temporal trends analysis. World Neurosurg. 2023 Feb;170:e1-8. doi: 10.1016/j.wneu.2022.07.095.

Surachman AJD, Yanuarso, Akbar DL. Emergency decompression and stabilization of 1st thoracic spinal cord injury and sacral fracture in a Covid-19 patient: a case report. Int J Surg Case Rep. 2021 Apr;81:105670. doi: 10.1016/j.ijscr.2021.105670.

Fehlings MG, Vaccaro A, Wilson JR, Singh A, Cadotte DW, Harrop JS, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS One. 2012;7(2):e32037. doi: 10.1371/journal.pone.0032037.

RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Feb 12;399(10325):665-76. doi: 10.1016/S0140-6736(22)00163-5.

Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant. J Infect Chemother. 2022 Sep;28(9):1344-6. doi: 10.1016/j.jiac.2022.05.012.